/
/
/
A New Method To Detect IDH1 Synonymous SNP 105 C >T rs11554137

A New Method To Detect IDH1 Synonymous SNP 105 C >T Rs11554137

Short CommunicationsNov 12, 2018Vol. 18 No. 3 (2018)

Abstract

Alteration of cellular metabolism is one of the oncogenetic mechanisms. Furthermore, the defect of Isocitrate dehydrogenase (IDH) enzymes lead to abnormal cellular metabolism. Mutation in the IDH1 gene is common in glioblastoma multiforme (GMB), glioma, and acute myeloid leukemia (AML). The IDH1 single nucleotide polymorphism (SNP) in codon 105 C>T (rs11554137) is a prognostic factor in patients with glioma and AML. Currently, the most common technique used for IDH1 SNP 105 C>T detection is the sequencing technique that expensive and time-consuming. We designed a new method through the Restriction fragment length polymorphism (RFLP). Ninty Eight unrelated healthy volunteers comprising of 49 male, and 49 female which was randomly selected. Their ages ranged from 1 to 64 years with a median age of 33 years. Polymerase chain reaction (PCR) and RsaI fragmented IDH1 SNP105 C >T were identified in 16.3% of our cases. So we conclude that we may use the PCR-RFLP assay instead.

How to Cite

Mohamed, A. F. ., Ali*, Y. B. ., Ebid, G. T. ., & Guirgis, A. A. . (2018). A New Method To Detect IDH1 Synonymous SNP 105 C >T rs11554137. CURRENT APPLIED SCIENCE AND TECHNOLOGY, 192-199.

References

  • Dang, L., Jin, S. and Su, S.M., 2010. IDH mutations in glioma and acute myeloid leukemia. Trends in Molecular Medicine, 16(9), 387-397.‏
  • Patel, K.P., Barkoh, B.A., Chen, Z., Ma, D., Reddy, N., Medeiros, L.J. and Luthra, R., 2011. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia: an algorithmic approach using high-resolution melting curve analysis. The Journal of Molecular Diagnostics, 13(6), 678-686.‏
  • Ravandi, F., Patel, K., Luthra, R., Faderl, S., Konopleva, M., Kadia, T., Brandt, M., Pierce, S., Kornblau, S., Andreeff, M., Wang, X., Garcia-Manero, G., Cortes, J. and Kantarjian, H., 2012. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high‐dose cytarabine and idarubicin. Cancer, 118(10), 2665-2673.‏
  • Chang, C.M., Xu, K. and Shu, H.K.G., 2011. The role of isocitrate dehydrogenase mutations in glioma brain tumors. In: M. Garami, ed. Molecular Targets of CNS Tumors. London: InTechOpen, pp. 413–436.‏
  • Rakheja, D., Konoplev, S., Medeiros, L.J. and Chen, W., 2012. IDH mutations in acute myeloid leukemia. Human Pathology, 43(10), 1541-1551.‏

Author Information

Ahmed F.K. Mohamed

Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Sadat City, Egypt

Yasser B.M. Ali*

Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Sadat City, Egypt

Gamal T. Ebid

Clinical pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt

Adel A. Guirgis

Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Sadat City, Egypt

About this Article

Journal

Vol. 18 No. 3 (2018)

Type of Manuscript

Short Communications

Keywords

IDH, SNP, RFLP, AML, Glioma

Published

12 November 2018